The Effect of Coffee on People with High Intensity Exercise and the Characteristics of Caffeine Metabolism
Launched by SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY ,CHINESE ACADEMY OF SCIENCES · Nov 26, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how coffee affects exercise performance and how our bodies process caffeine. Researchers want to understand if drinking coffee can help people perform better during high-intensity workouts and how different individuals metabolize caffeine. The trial is currently looking for healthy adults aged 18 to 40 years old to participate.
To join the study, participants must be in good health and not have any recent surgeries or ongoing medical conditions that require long-term medication. If you participate, you can expect to take part in exercises while consuming coffee and share your experiences with the research team. This study could provide valuable insights into the benefits of coffee for exercise, and your participation could help others understand its effects better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy adults 18-40 years old
- Exclusion Criteria:
- • Diabetes Hypoglycemia Gout Osteoporosis Gastric ulcer Pancreatitis Intestinal obstruction Blood phobia Pathological hypo or hyper tension Impaired glucose tolerance Claustrophobia HIV,etc.
About Shenzhen Institutes Of Advanced Technology ,Chinese Academy Of Sciences
The Shenzhen Institutes of Advanced Technology (SIAT), part of the Chinese Academy of Sciences, is a leading research institution dedicated to advancing scientific knowledge and technology across various fields, including biomedical research. SIAT is committed to fostering innovation through interdisciplinary collaboration and state-of-the-art facilities, focusing on the translation of research into practical applications. With a strong emphasis on clinical trials and regulatory compliance, SIAT aims to contribute to the global healthcare landscape by developing novel therapies and solutions that address pressing medical challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shenzhen, Guangdong, China
Patients applied
Trial Officials
John R Speakman, PhD
Study Chair
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported